Novoron Bioscience is developing NOVO-118, a lead drug candidate that has shown potential to promote axonal regeneration and repair the myelin sheath. The company’s platform targets a family of LDLR receptors long considered difficult for drug development, and the technology could have applications beyond CNS diseases, including cardiac remodeling, cancer, and ophthalmic disease. Novoron’s most advanced program is in spinal cord injury (SCI), where in vivo studies showed treatment with NOVO-118 produced significant improvement in motor function; it is also being developed as a putative remyelination therapy for multiple sclerosis (MS). The company is finalizing preclinical proof-of-concept studies for NOVO-118 in both MS and SCI and is on track to enter clinical trials within the next three years. Novoron is led by CEO and co-founder Travis Stiles, PhD, and is based in San Diego, California. Financially, the company has received seed investments and grant funding to support its preclinical development. Novoron Bioscience is a San Diego startup focused on remyelination to treat multiple sclerosis. Its lead compound, NOVO-117, targets the molecule RhoA, which inhibits natural remyelination via oligodendrocyte precursor cells. The company is in preclinical development and aims to stimulate nerve regeneration by restoring myelin sheaths. Novoron recently won a $680,000 SBIR grant from the National Institutes of Health to expand its preclinical work over two years. Beyond multiple sclerosis, the startup is also pursuing related therapeutics for glaucoma and spinal cord injury. The report notes Biogen is testing a separate drug that can restore myelin, while Novoron is advancing its own candidate.

Total raised

$4M

Funding rounds

2

Latest round

Seed

Latest activity

Nov 2021